Type of site | Prescription drug marketplace |
|---|---|
| Available in | English |
| Owner | White House Office |
| URL | trumprx.gov |
TrumpRx is a prescription drug website operated by the United States federal government.
Type of site | Prescription drug marketplace |
|---|---|
| Available in | English |
| Owner | White House Office |
| URL | trumprx.gov |
TrumpRx is a prescription drug website operated by the United States federal government.
In September 2025, Bloomberg News reported that Trump administration officials were considering establishing a website to partially fulfill U.S. president Donald Trump's demands that drugmakers reduce their prices to levels set by other countries. [1] On September 30, Trump announced TrumpRx from the Oval Office, joined by Pfizer chief executive Albert Bourla. [2] The website was set to go online in January 2026. [3]
TrumpRx is a website that offers prescription drugs at a discounted price. [2] The prices are benchmarked against those in Europe. [3] Pfizer's negotiated discounts ranged from fifty to eighty-five percent. [4]
The website does not sell drugs directly. Rather, it enables consumers to buy specific prescription medications directly from pharmaceutical companies at reduced prices, without going through their insurance. The aim is to reduce out-of-pocket expenses for consumers, especially those who pay cash or do not have extensive drug coverage. [5]
According to an initial statement from the Trump administration, TrumpRx will provide Eucrisa, Xeljanz, and Zavzpret. [2] In October 2025, the Trump administration reached a deal with AstraZeneca; [6] a website from AstraZeneca, named AstraZeneca Direct, [7] included Farxiga, Airsupra, and FluMist as eligible for direct pricing. [6] That month, EMD Serono agreed to offer its gonadotropin preparation drugs, including Gonal-f, [8] on TrumpRx. [9] AmgenNow, a website from Amgen that offers Repatha, is additionally set to appear on TrumpRx. [10]
Bloomberg News described TrumpRx as an instance of Trump using the federal government as an avenue for shareholder activism. [11]
The deal reached with the Trump administration secured Pfizer a reprieve from tariffs on the pharmaceutical industry, threatened to be one hundred percent. [12]
According to The New York Times , TrumpRx does not provide meaningful discounts for insurance beneficiaries. [13]